FDA Approves Targeted First-Line Therapy for BRAF V600E–Mutant Metastatic Colorectal Cancer
- Feb 26
- 1 min read
Publisher name
LinkedIn (Spencer Knight)
The U.S. Food and Drug Administration has granted full approval for encorafenib in combination with cetuximab and fluorouracil-based chemotherapy as a first-line treatment for BRAF V600E–mutant metastatic colorectal cancer. The approval is supported by Phase 3 data demonstrating improved overall and progression-free survival compared with standard chemotherapy, marking a regulatory milestone for this high-risk molecular subgroup.
👉 Read the full article: Pfizer scores FDA full approval for BRAFTOVI® in combination therapy for BRAF V600E–mutant metastatic colorectal cancer
Disclaimer
Images are illustrative only. This content does not constitute medical advice. SSCTR is not responsible for clinical or regulatory decisions. The content is provided for informational and educational purposes only.
Comments